Pérez CM, Alonso RA, González OE

Idioma: Español
Referencias bibliográficas: 51
Paginas: 1-11
Archivo PDF: 450.40 Kb.

RESUMEN

El cáncer de ovario es una de las neoplasias más letales dentro de los cánceres ginecológicos con altos niveles de resistencia a los tratamientos habituales. La identificación de blancos tumorales para terapias biológicas responde a la necesidad de desarrollar nuevas estrategias terapéuticas contra este tipo de tumor. Diferentes estudios han demostrado que existe asociación entre la expresión del ligando de EGF, así como sus receptores y el pronóstico de las pacientes con cáncer de ovario. Altos niveles de EGFr se asocian a proliferación, invasión, metástasis y resistencia a la quimioterapia. El uso de productos anti-EGF, como la vacuna CIMAvax-EGF, podría resultar beneficioso en el tratamiento del cáncer de ovario, lo que constituye una opción terapéutica para estas pacientes.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Suarez García R, Pérez Martínez C, Fernández Rojas L, Pérez Pupo A. Caracterización de adultos mayores con cáncer de cabeza y cuello. CCM. 2013;17(2):1-15

2. Landen C, Birrer M, Sood A. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008;26(6):995-05.

3. Vaughn S, Coward J, Bast R, al e. Rethinking ovarian cancer: Recommendations for improving outcomes. Nature Rev. 2011;11:719-725.

4. Yu J, Ma Y, Drisko J, Chen Q. Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Carboplatin Effects Against Ovarian Cancer. Curr Ther Res Clin Exp. 2013;75:8-14.

5. Siegel R, Miller K, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.

6. Anurio Estadístico de Salud 2014. La Habana: MINSAP, Departamento de Registros Médicos y Estadística en salud; 2015.

7. Clavijo Rodríguez T, Lugones Botell M, Guevara Alfayate L, Berlán León N. Aspectos clínicos y epidemiológicos de los tumores anexiales. Revista Cubana de Ginecología y Obstetricia. 2012;38(2):221-28.

8. E L. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):10531064.

9. Badgwell D, Bast R. Early detection of ovarian cancer. Dis. Markers. 2007;23:397-10.

10. Huckabay H, Wildgen S, Dunn R. Label-free detection of ovarian cancer biomarkers using whispering gallery mode imaging. Biosens. Bioelectron. 2013;45:223-29.

11. Bruchim I, Ben-Harim Z, Piura E, Tepper R, Fishman A. Preoperative clinical and radiological features of metastatic ovarian tumors. Arch. Gynecol. Obstet. 2013:10.1007.

12. Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D. On behalf of the Australian Ovarian Cancer Study Group; Obermair, A. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecol. Oncol. 2013:10.1016.

13. Jensen M, Erichsen K, Björkling F, Madsen J, Jensen P, Sehested M, et al. Imaging of treatment response to the combination of Carboplatin and Paclitaxel in Human Ovarian Cancer Xenograft Tumor in mice using FDG and FLT PET. PLoS ONE. 2013;8(12):e85126.

14. Oseledchyk A, Zivanovic O. Intraoperative Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer. Cancer Network. 2015.

15. Shelly D, Epari S, Arora I, Pai T, Ahmed S, Moiyadi A. Epidermal growth factor receptor (EGFR) gene amplification in high-grade gliomas: Western Indian tertiary cancer center experience. Neurol India. 2016; 64(1):115-20.

16. Montgomery R, Queiroz L, Rogerio F. EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation. Arq Neuropsiquiatr. 2015;73(7):561-68.

17. Rodríguez P, Rodríguez G, González G, Lage A. Clinical development and Perspectives of CImAvax EGF, Cuban Vaccine for Non-small-cell Lung Cancer therapy. MEDICC Review. 2010;12(1):17-23.

18. Cheng J, Kananathan R. CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma. Human Vaccines & Immunotherapeutics. 2012;8(12):1799-01.

19. Fernández Lorente A, Acosta Brooks S, Neninger Vinageras E, Barroso Alvarez M, Wilkinson Brito B, Troche Concepción M, et al. Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF. Journal of Surgical Oncology. 2013;11:275.

20. Pérez R, Moreno E. EGFR-targeting therapy as an evolving concept: learning from nimotuzumab clinical development. Chin Clin Oncol. 2014;3(1):5.

21. Cetina L, Crombet T, Jiménez-Lima R, Zapata S, Ramos M, Avila S, et al. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. Cancer Biology & Therapy. 2015; 16(5):684-89.

22. Karst A LKDR. Modeling high-grade serous ovarian carcinogenesis from the. Proc Natl Acad Sci USA. 2011;108(18):7547-52.

23. Shih I, Ho C, Nakayama K, Salani R. Pathogenesis and new therapeutic targets of ovarian. J. Oncol. 2012:867512.

24. Mountain C, Hermes K. Surgical treatment of lung cancer. Past and present. Methods Mol Med. 2003;75:453-87.

25. Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, et al. Histological classification of ovarian cancer. Med. Electron. Microsc. 2003;36:9-17.

26. Tatar B, Boyraz G, Selçuk I, Doğan AK, Usubütün A, Tuncer ZS. In vitro chemosensitivity in ovarian carcinoma: Comparison of three leading assays. J Turk Ger Gynecol Assoc. 2016;17:35-40.

27. Lax S. Serous genital carcinoma: Molecular pathogenesis and the role of tubal fimbria. Pathologe. 2009;30:210-16.

28. McCluggage W. My approach to and thoughts on the typing of ovarian carcinomas. J. Clin. Pathol. 2008;61:152-63.

29. Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. British Journal of Cancer. 2011;104:1241-45.

30. Appert-Collin A, Hubert P, Crémel G, Bennasroune A. Role of ErbB Receptors in Cancer Cell Migration and Invasion. Frontiers in Pharmacology. 2015;6(283):1-10.

31. Prenzel N, Fischer O, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001;8(1):11-31.

32. Hynes N, Lane H. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-54.

33. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello M, De Luca A. The ErbB receptors and their ligands in cancer an overview. Curr Drug Targets. 2005;6(3):243-57.

34. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7. 2002; 4:2-8.

35. Olayioye M, Neve R, Lane H, Hynes N. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J. 2000;19(13):3159-67.

36. Biswas D, Cruz A, Gansberger E, Pardee A. Epidermal growth factor- induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A. 2000;97(15):8542-47.

37. Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl A, Sehouli J, et al. An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer. 2011;11:294.

38. Yin M, Li X, Tan S, Zhou H, Ji W, Bellone S, et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016; pii: 87252.

39. Grassi M, Palma C, Thomé C, Lanfredi G, Poersch A, Faça V. Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control. J Proteomics. 2016; pii: S1874-3919(16)30248-2.

40. Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J. Targeting Signaling Pathways in Epithelial Ovarian Cancer. Int. J. Mol. Sci. 2013;14:9536-55.

41. Reyes H, Thiel K, Carlson M, Meng X, Yang S, Stephan J, et al. Comprehensive Profiling of EGFR/HER Receptors for Personalized Treatment of Gynecologic Cancers. Mol Diagn Ther. 2014;18(2):137-51.

42. Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger P, Markakis S. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res. 2005;11:8637-43.

43. Zhang M, Zhuang G, Sun X, Shen Y, Zhao A, Di W. Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics. Journal of Ovarian Research. 2015;8:67.

44. Showeil R, Romano C, Valganon M, Lambros M, Trivedi P, Van Noorden S, et al. The status of epidermal growth factor receptor in borderline ovarian tumours. Oncotarget. 2016;7(9):10568-77.

45. Ranjbar R, Nejatollahi F, Nedaei Ahmadi A, Hafezi H, Safaie A. Expression of

46. Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance. Iran J Cancer Preven. 2015; 8(4):e3428.

47. Puvanenthiran S, Essapen S, Seddon A, Modjtahedi H. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs. International J of Oncol. 2016;49:1825-38.

48. Ignacio R, Kabir S, Lee ES, Adunyah S, Son DS. NF-κB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression. PLoS ONE. 2016;11(10):e0164189.

49. Huang WL, Li Z, Lin TY, Wang SW, Wu FJ, Luo CW. Thyrostimulin-TSHR signaling promotes the proliferation of NIH:OVCAR-3 ovarian cancer cells via trans-regulation of the EGFR pathway. Scientific Reports. 2016;6:27471.

50. Li D, Wu Q, Bi F, Chen S, Zhou Y, Zhao Y, et al. Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer. Am J Transl Res. 2016;8(3):1601-08.

51. Granados M, Hudson L, Samudio-Ruiz S. Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells. PLoS ONE. 2015;10(9):e0136893.